Congenital disorders of glycosylation (CDG) are a group of autosomal
recessive genetic disorders caused by the alteration in synthesis and
structure of protein and lipid glycosylation. In the past decade, over
30 genetic diseases have been identified that alter glycan synthesis,
structure and ultimately the function of nearly all organ systems.
CDG type I (CDGI) disorders result from impaired synthesis of the
incomplete lipid linked oligosaccharide (LLO) and/or its attachment to
the growing polypeptide chain. CDG-Ia is the most common form reported,
due to phosphomannomutase deficiency, an enzyme that converts
mannose-6-phosphate to mannose-1-phosphate. CDG-Ib (phosphomannose
isomerase, MPI deficiency) is the only known treatable form, by giving
mannose orally. CDG type II (CDGII) includes defects in processing of
Phenotypes of this disorder are extremely variable. Manifestations
range from severe developmental delay and hypotonia with multiple organ
system involvement beginning in infancy, to hypoglycemia and
protein-losing enteropathy with normal development. Most subtypes have
been described in only a few individuals, however, thus understanding of
the phenotypes is limited.
The current diagnostic test for CDG is analysis of serum transferrin
glycoforms, also called "transferrin isoforms analysis", or
"carbohydrate-deficient transferrin analysis." If positive, this testing
can be followed by DNA testing to identify mutations in the gene
involved. If a sample is not available for biochemical testing or if
biochemical test results are inconclusive, this panel offers next generation sequence of CDG-associated genes.
- Freeze HH. Congenital disorders of glycosylation: CDG-I, CDG-II, and beyond. Curr Mol Med 2007; 7:389-396.
- GeneTests: Congenital Disorders of Glycosylation Overview
- Jaeken J, Matthijs G. Congenital disorders of glycosylation: A rapidly expanding disease family. Annu Rev Genomics Hum Genet 2007; 8:261-278.
This test is indicated for:
- Confirmation of a clinical/biochemical diagnosis of a CDG, or when CDG is suspected and biochemical results are unavailable or inconclusive.
- Carrier testing in adults with a family history of a CDG.
Please note that a "backbone" of probes across the entire genome are included on the array for analytical and quality control purposes. Rarely, off-target copy number variants causative of disease may be identified that may or may not be related to the patient's phenotype. Only known pathogenic off-target copy number variants will be reported. Off-target copy number variants of unknown clinical significance will not be reported.
Submit only 1 of the following specimen types
Preferred specimen type: Whole Blood
Type: Whole Blood
Specimen Requirements:In EDTA (purple top) or ACD (yellow top) tube:
Infants (<2 years): 2-3 ml
Children (>2 years): 3-5 ml
Older Children & Adults: 5-10 ml.
Specimen Collection and Shipping: Refrigerate until time of shipment. Ship sample within 5 days of collection at room temperature with overnight delivery.
Type: Isolated DNA
Specimen Requirements:In microtainer: 10 ug
Isolation using the QiagenTM Puregene kit for DNA extraction is recommended.
Specimen Collection and Shipping: Refrigerate until time of shipment in 100 ng/ul of TE buffer. Ship sample at room temperature with overnight delivery.
Submit copies of diagnostic biochemical test results with the sample,
if appropriate. Contact the laboratory if further information is
- Individual sequence analysis and deletion/duplication analysis is available for each of the genes in the panel.
- Congenital Disorders of Glycosylation: Sequencing Panel.
- Biochemical testing for CDGs is available. See the test menu for details.
- Custom diagnostic mutation analysis (KM) is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.
- Prenatal testing is available to adult couples who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.